REG - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

31/08/2023 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230831:nRSe9914Ka&default-theme=true

RNS Number : 9914K  Physiomics PLC  31 August 2023

31 August 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Contract Award

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company,
supporting development of oncology drugs and personalised medicine solutions,
is pleased to announce that it has been awarded its first contract with a new
UK-based biotech client.  The contract, which has a value of £125,000 and
relates to a project in the immune-oncology field, is expected to be completed
within this calendar year.

 

Physiomics CEO, Dr Jim Millen, commented:

"We are delighted to have been chosen by this new client to support the
development of its lead asset.  We look forward to working with them on this
exciting project."

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.

 

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design of pre-clinical and clinical studies.

 

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 projects, over 40
targets and 70 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEAFPFDLEDEFA